Hippocratic AI, a generative AI company focused on healthcare, has secured $141 million in a Series B funding round led by Kleiner Perkins, raising its valuation to $1.64 billion. Existing investors, including NVIDIA, General Catalyst, and A16z, also participated at or above their pro-rata share. The capital will drive the company’s expansion into new verticals such as pharmaceuticals and payors, as well as into international markets in EMEA, Southeast Asia, and Latin America. Hippocratic AI has launched its AI Agent App Store, allowing clinicians to collaborate in creating AI agents tailored to specific healthcare tasks and earn revenue from their usage. These agents have already been deployed across major organizations like OhioHealth, Cincinnati Children’s, and Fraser Health, ensuring safety parity with human clinicians through rigorous testing.
Since its Series A funding nine months ago, Hippocratic AI has achieved significant milestones, including the release of its Polaris 2.0 architecture, which expanded the model’s intelligence parameters from 1.1 trillion to 3.7 trillion, and the issuance of its first U.S. patent. The company has signed contracts with 23 healthcare clients, launching 16 of them within 23 weeks, while maintaining close collaboration with systems like UHS, Memorial Hermann, and Honor Health to ensure patient safety. CEO Munjal Shah emphasized the company’s commitment to “healthcare abundance” through GenAI-driven staffing solutions, with this funding accelerating their efforts to deploy scalable and safe AI technologies globally.